US Stem Cell Inc (USRM)

[jcabrer]

Positive q3 results:
Financial highlights from 2016 include:

Revenue up by 38% from $2.2M in 2015 to $3.03M in 2016
Current liabilities down by $1.9M or 23.8% from $8.0M in 2015 to $6.1M in 2016
Operating Expenses down 16.5% (or $631,825) from 3.82M in 2015 to $3.19M in 2016
Net loss improved 136% from $2.6M (gain) in 2015 to $1.15M in 2016
And for the first time in the company’s history, U.S Stem Cell, Inc. ended the year on a cash positive note: $108,596 cash positive as a result of operations in 2016 compared to $844,690 cash negative from operations in 2015
Operating results for the year ending December 31, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31, 2017.